Crizanlizumab study for sickle cell anemia
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a medicine called crizanlizumab to see if it helps improve oxygen delivery in people with sickle cell anemia. It may help reduce pain crises and other complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have sickle cell anemia (type SS or Sβ0)
- You are at least 16 years old
- You can have an MRI without needing sedation
- You have not had a pain crisis or needed a blood transfusion in the past 4 weeks
- You are not currently on chronic transfusion therapy
- You are not pregnant and do not have a seizure disorder or other serious chronic illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This program provides crizanlizumab, a medicine that may help reduce pain crises in sickle cell disease, to patients who have no other treatment options and cannot join a clinical trial. It is a special access program for individual patients.
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This Phase 1/2 study tests a CRISPR-edited bone marrow (stem cell) transplant to treat severe sickle cell disease. It aims to reduce dangerous sickle-related complications by changing the patient’s stem cells before transplant.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.